Form 4: Doximity Director Sells Shares After Option Exercise

Doximity Director Kira Scherer Wampler exercised stock options, converted Class B shares to Class A, and subsequently sold 2,000 Class A shares for $26 each under a pre-arranged trading plan.

Summary

• Kira Scherer Wampler, a Director at Doximity, Inc. (DOCS), engaged in multiple transactions on March 3, 2026.
• Exercised stock options to acquire 2,000 shares of Class B Common Stock at an exercise price of $1.54 per share.
• Converted 2,000 shares of Class B Common Stock into 2,000 shares of Class A Common Stock.
• Sold 2,000 shares of Class A Common Stock at a price of $26.00 per share, totaling $52,000.
• The sale was executed automatically pursuant to a Rule 10b5-1 trading plan adopted on November 12, 2024.
• Following these transactions, Wampler beneficially owns 19,839 shares of Class A Common Stock and 456,700 derivative securities (stock options) related to Class B Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, typical for directors managing personal finances through pre-arranged trading plans, and not indicative of specific positive or negative company performance.

Positives

• Director Wampler exercised stock options, indicating a realization of value from previously granted equity compensation.
• The sale was conducted under a Rule 10b5-1 plan, suggesting a pre-planned diversification or liquidity event rather than an immediate reaction to new, potentially negative, information.

Negatives

• A director selling shares reduces their direct equity stake in the company, which some investors might interpret as a lack of conviction, though this is often a routine part of executive compensation management.

Future Outlook

N/A

Industry Context

StockSavvy.ai notes that insider transactions, especially sales, are common for directors and executives for diversification or liquidity, particularly when executed under a Rule 10b5-1 plan, which helps mitigate concerns about trading on material non-public information. This is a routine disclosure for a publicly traded company like Doximity in the healthcare technology sector.

Comparison to Industry Standards

• Insider sales under 10b5-1 plans are a standard practice across industries for executives and directors to manage their equity holdings and personal finances.
• Similar planned sales are routinely observed at major technology companies such as Microsoft (MSFT) or Apple (AAPL), where executives diversify their compensation and manage tax liabilities.
• The specific sale price of $26.00 per share for Doximity (DOCS) would typically be assessed against the company's historical trading range and prevailing analyst price targets to gauge its perceived value at the time of the transaction.

Stakeholder Impact

• Shareholders: The sale represents a director reducing their direct equity holdings, which is a common practice for diversification. Given it's a 10b5-1 plan, it typically has a neutral impact on investor sentiment.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction by a director, involving the exercise of stock options and subsequent sale of shares under a pre-established 10b5-1 trading plan. Such transactions are common for executives managing personal liquidity and diversification and typically do not signal a change in the company's fundamental outlook or warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

Doximity, DOCS, Form 4, insider trading, stock options, share sale, director, Kira Scherer Wampler, 10b5-1 plan